Over the last decade, molecular biology has progressively developed, leading to new technology with subsequent clinical application for various cerebral diseases including Parkinson's disease (PD), one of the most investigated neurodegenerative disorders. The therapy for PD is mainly composed of medication, including drug replacement therapy, surgical treatment, and cell transplantation. Cell therapy for PD has been explored by using fetal nigral cells as an allo-or xenograft, autologous sympathetic ganglion, adrenal medulla, and carotid body in clinical settings. In addition, neurotrophic factors, including glial cell line-derived neurotrophic factor (GDNF), have a strong potency to rescue degenerating dopaminergic cells. Protein and/or gene therapy also might be a therapeutic option for PD. In this review, genetically engineered cell transplantation for animal models of PD, including catecholamine/neurotrophic factor-secreting cell transplantation with or without encapsulation, as performed in our laboratories, and their potential future as clinical applications are described with recent clinical studies in this field.
INTRODUCTION
then, clinical studies using cell transplantation from various sources and protein therapy as well as medication using L-DOPA, dopamine agonist, or other agents, have The pathology of Parkinson's disease (PD) is neurodegeneration of the nigrostriatal system, manifesting itself been reported (4,12,19,21,23,44,46,52,57) ( Table 1 ). Fetal nigral cell transplantation is performed with the in-as a triad of rigidity, tremor, and akinesia (9). Dopamine replacement therapy (DRT) using L-dihydroxyphenylala-tention to achieve synapse formation with preserved host neurons by the elongation of the neural processes of nine (L-DOPA) was the first established therapy for PD, although long-term administration caused side effects of transplanted donor cells, as well as to supply dopamine (DA). It was considered a newly developed, effective, dyskinesia or wearing-off (30) . Stereotaxic surgery, including deep brain stimulation and electrical coagula-and safe therapy at the end of the 20th century, in spite of the ethical issues of using aborted fetuses or immuno-tion, has also been shown to be an effective therapeutic option for PD (7, 62) . Current developments in molecular logical problems such as those seen with allogeneic grafts (33, 37) . Then in the new millennium, reports of random-biology and recent breakthroughs in stem cell research have brought us closer to the day when cell transplanta-ized, double blind studies revealed the insufficient functional recovery of older patients and delayed dyskinesia tion will be widely recognized as a feasible therapy for PD (29, 32) . In this article, we review recent clinical in some patients, although both good survival of the transplanted cells in autopsy cases and the ameliorated studies on PD and report on animal studies using genetically engineered cells performed in our laboratory, along DA uptake, as confirmed by positron emission tomography (PET) using 18 F-fluorodopa (19, 36, 44) , have been with their future potential directions.
reported. However, a recent report presents an even more CLINICAL STUDY FOR PD FROM THE optimistic aspect of fetal nigral transplantation using a VIEWPOINT OF REGENERATION cell suspension rather than solid tissue, as performed in the previous randomized, double blind studies (39). The In 1988, two groups reported the clinical application of fetal nigral cell transplantation for PD (33,37). Since two patients showed ameliorated Unified Parkinson's 126 YASUHARA AND DATE Disease Rating Scale (UPDRS) motor score, a reduction will be one of the most hopeful candidates for PD therapy in the near future (22, 29, 32 ,54) ( Fig. 1 ). of dyskinesia induced by L-DOPA, and no dyskinesia in the off state, subsequently with many surviving trans-Alternatively, intraparenchymal injection of GDNF has been demonstrated as another hopeful therapeutic planted cells and a very mild immune reaction even at about 4 years posttransplantation. Furthermore, the im-option for PD patients, although there is some controversy. After the pilot study of Gill and colleagues (21), portance of phenotypes in surviving DA neurons was recognized (39). some groups have reported its effectiveness and safety (34, 46, 57) , although intraventricular administration of Autologous cell transplantation using various tissues has been reported as potential treatment for PD (4,12,23).
GDNF demonstrated no improvement in a randomized, double blind study (42) . Previously, we demonstrated Arjona and colleagues performed a pilot study using intrastriatal transplantation of the autologous carotid body that intrastriatal injection of GDNF was more effective than intraventricular administration in animal models of to patients with advanced stage PD (Hoehn and Yahr score ≥ 3) (4). Bilateral intrastriatal transplantation was PD (2). Patel and colleagues demonstrated the safety and effectiveness of GDNF administration for 2 years (46) . performed in six PD patients with pre-and posttransplant (18 months) evaluation. No patients demonstrated
In addition, Slevin and colleagues reported that unilateral GDNF administration ameliorated bilateral function side effects, including dyskinesia. In addition, five of the six patients showed the ameliorated UPDRS III during with no severe side effects (57). Furthermore, neuronal sprouting was confirmed in the nigrostriatal area of one their off-state. The carotid body is a paraneuron derived from the neural crest similar to chromaffin cells of the patient who received unilateral GDNF infusion for 43 months and died of a myocardial infarction 3 months adrenal medulla. Glial-derived neurotrophic factor (GDNF) secreted from the carotid body might be impor-after discontinuing treatment (34) . In years to come, the results of longer follow-up studies or cases with discon-tant for the neuroprotective effects of these transplanted cells (60). The strategy of using autologous carotid body tinuation of GDNF administration will be obtained and thus the future potential of GDNF therapy will be deter-transplants might be feasible because of its simplicity and safety without the concern of ethical issues, al-mined.
There are almost no reports of in vivo clinical studies though a randomized, double blind study with more patients is required for its accurate estimation. Further-using viruses as vectors for PD patients. During and colleagues performed their study using glutamate decarbox-more, transplantation using autologous neural stem cells with precise control of differentiation to DA neurons ylase (GAD) and have obtained FDA approval for the world's first human phase I clinical trial using a gene lizing a variety of different methods. Cell therapy using the encapsulation technique might be one of the more therapy approach for PD. In their study, the GAD gene was transferred to the subthalamic nucleus (STN) using hopeful strategies for clinical application. Aebischer and colleagues demonstrated the effectiveness and safety of an adenoassociated virus (AAV). This results in the expression of the well-known inhibitory neurotransmitter, encapsulated ciliary neurotrophic factor (CNTF)-producing cell transplantation in amyotrophic lateral sclerosis gamma-amino butyric acid (GABA), with subsequent suppression of the pathologic excitation of the STN, as (ALS) patients (1) . A number of researchers have been pursuing the studies of encapsulated cell transplantation demonstrated using rodent models of PD (17, 35) . This study might reveal some of the beneficial mechanisms in diseases of the central nervous system (CNS), including PD and cerebral ischemia (13,14,20,25,26,53,63,64, of deep brain stimulation of the STN as well as lead to a hopeful therapeutic option for PD treatment in the 69, 70) . Encapsulated cell transplantation is characterized as future.
follows. 1) Various neurotransmitters, neurotrophic fac-INTRACEREBRAL TRANSPLANTATION tors, or growth factors can be produced continuously OF ENCAPSULATED CELLS from encapsulated cells with tailored properties. Cells inside the capsule are supplied sufficient nutrients and As briefly described in the previous sections, clinical studies have been performed and are now ongoing, uti-oxygen through a semipermeable membrane and are ca- The encapsulation technique can also be used for the supply of factors with no concern of tumorigenesis and immune rejection. The transplanted cells (unless encapsulated) can achieve reinnervation with host tissue, work as a neuroprotectant, or activate endogenous neurogenesis. GDNF infusion into the putamen or gene transfer to the subthalamic nucleus might also alter the microenvironment in a favorable way, as well as surgery, such as deep brain stimulation (DBS) and electrical coagulation. Subsequently, these therapies will reduce doses of medication, slow the progression of symptoms, or improve function. Finally, PD patients with a reduced activity of daily life (ADL) might be able to improve their ADL. ADL, activity of daily life; DA, dopamine; DBS, deep brain stimulation; ES, embryonic stem cells; GDNF, glial cell linederived neurotrophic factor; GPi/GPe, globus pallidus interna/externa; SNc, substantia nigra pars compacta; STN, subthalamic nucleus.
pable of secreting factors out of the capsule. 2) No im-Tet-Off) in which human tyrosine hydroxylase (TH) expression can be negatively controlled by Dox adminis-munological rejection arises because the cells inside are protected by a stiff envelope. The molecular sieve of the tration. The amount of catecholamine secretion from the cell line was confirmed to be decreased by Dox adminis-capsule prevents immunocompetent cells from invading and attacking the donor cells inside the capsule. 3) Tu-tration in a dose-responsive manner. Reverse transcription-polymerase chain reaction (RT-PCR) also revealed morigenesis does not occur because donor cells cannot get out of the capsule. 4) The capsule can be removed that the expression of human TH was clearly reduced by Dox administration. In addition, the changeover of from the transplanted brain if any problems arise after transplantation. 5) Various cells, including immortalized catecholamine secretion by Dox administration was recognized for 70 days in vitro, although the control be-cell lines, can be transplanted safely as a surviving donor with no ethical problems. Some of these cells can came slightly less effective with time. Subsequently, encapsulated cells were transplanted into the striatum of also be genetically engineered with ease. 6) No synapse formation occurs between the donor cells and the host parkinsonian rats. The rats displayed behavioral improvement following catecholamine secretion from the tissue, although this might be a drawback. Thus, encapsulated cell transplantation is a useful delivery system capsule and they then deteriorated behaviorally after oral administration of Dox for 1 week. In addition, the cate-for the treatment of CNS diseases including PD.
cholamine concentration in the CSF was also controlled DOPAMINE SUPPLY WITH ENCAPSULATED by Dox administration with long-term survival of encap-CELL TRANSPLANTATION sulated cells, although these effects gradually reduced in vivo (submitted for publication). Based on the concept of DRT, catecholamine administration using the encapsulation technique was at-Alternatively, suicide gene transfer to transplanted cells using the Tet-Off or Tet-On system might be useful tempted in our laboratory. In order to increase the local concentration of catecholamine, PC12 cells, derived from in the prevention of tumorigenesis by transplanted cells (8,41), although their safety and usefulness in clinical rat pheochromocytoma, were encapsulated and transplanted into the striatum of parkinsonian monkeys (13eter). The settings still remains to be resolved by exhaustive preclinical studies. monkeys displayed ameliorated behavior for 12 months with the demonstration of a scant immunological reac-NEUROPROTECTIVE EFFECTS tion around the graft and survival of the cells inside the OF VEGF ON PD capsule. Thus, local DA supply with encapsulated cell transplantation might be effective and feasible.
Before the successful results obtained from GDNF infusion into PD patients over the past few years, the On the contrary, oversupply of DA for a long time might make the pathology of PD more complicated and neuroprotective and neurorescue effects of GDNF were explored, with considerable emphasis on the administra-sometimes worse. Patients with DRT for a long time often develop both dyskinesia and wearing-off (43) with tion route, timing, and dose using animal models in our laboratory (2,3,11,53,68). Recently, Eslamboli and col-impairment of synaptic DA metabolism in the putamen (48). In addition, two randomized, double blind studies leagues demonstrated that continuous low-level GDNF delivery using recombinant adenoassociated viral (AAV) using fetal nigral cell transplantation revealed that it sometimes induced dyskinesia in some severe PD pa-vectors provided optimal functional outcome (18), thus indicating that capsule grafting with the ability to deliver tients, although it certainly had some therapeutic effects (19,44). PET revealed that 18 F-fluorodopa uptake in the factors continuously at desired doses is also a potentially beneficial delivery system. putamen significantly increased in the patients developing persistent dyskinesia (36) . Thus, dyskinesia induced Recently, the neuroprotective effects of vascular endothelial growth factor (VEGF) on DA neurons were by DRT or fetal nigral cell transplantation might be associated with an oversupply of DA in a localized area, also clarified. VEGF was considered as a well-known angiogenic factor and the strong neuroprotective effects although other factors, including an immunological reaction, might affect dyskinesia in fetal nigral cell trans-upon ischemic neurons (24) or its involvement in neurogenesis has been demonstrated (51, 58) . However, thus plantation (27) . If control of catecholamine secretion can be achieved, the side effects of DRT on PD patients far only a few studies have been reported about the effects of VEGF on DA neurons. Silverman and col-might be reduced and the safety of the transplantation will be further improved.
leagues demonstrated that VEGF showed neuroprotective effects on rat mesencephalic explant cultures. The From that point of view, we pursued the study of cell lines, in which catecholamine secretion could be con-indirect neuroprotective capacity of VEGF through angiogenesis and glial proliferation is suggested, although trolled by doxycycline (Dox) administration using the Tet-Off system. We established a PC12 cell line (PC12TH the direct protective effect via flk-1 was not clarified (56) . On the other hand, Pitzer demonstrated that VEGF brain edema in an in vivo study, although 1 and 10 ng/ ml of VEGF in vitro and 8 ng of VEGF from the small administration to ventral mesencephalon (VM) cell cultures with reduced glial cells in vitro increased the num-capsule in vivo displayed strong neuroprotective effects. This study suggests that continuous administration of ber of surviving DA neurons, although pretreatment of VEGF by a single injection into the rat striatum failed low-dose VEGF is essential for neuroprotection and that the therapeutic dose window is not very wide. This hy-to ameliorate survival of DA neurons in the solid E14 ventromedial (VM) grafts (47) .
pothesis has also been verified by other groups (38,45) . Furthermore, the neurorescue effect of VEGF upon Following on from these reports, we previously reported the neuroprotective effects of VEGF on DA neu-damaged DA neurons was demonstrated when VEGF was administered after 6-OHDA lesion both in vitro and rons in vitro and in vivo (65) . Pretreatment of 1 and 10 ng/ml of VEGF ameliorated cell survival of cultured DA in vivo (66). VEGF has strong effects upon endothelial cells, glial cells, and neurons, thus suggesting its poten-neurons from embryonic murine VM against the exposure of 6-hydroxydopamine (6-OHDA), which is a neu-tial for clinical application in the brain, as an ischemic limb or heart is also a good target of VEGF in clinical rotoxin for DA neurons, through suppression of apoptotic cell death. The neuroprotective effects of VEGF were practice (40, 49) . However, VEGF might be a doubleedged sword, especially when used in the brain; thus, explored using a rat model of PD. We established a cell line secreting VEGF by genetic manipulation using a we should bring forward preclinical studies in a prudent manner. cationic liposome-mediated DNA delivery method, which we encapsulated and grafted into the right striatum of GDNF-SECRETING STEM CELL host rats. At 1 week posttransplantation, rats received 6-TRANSPLANTATION IN PD OHDA in the right striatum with subsequent behavioral and immunohistochemical investigations. VEGF was se-Various stem cells are known to have the potency to renew themselves, to migrate where they are required, creted continuously from the retrieved capsule at 9 weeks posttransplantation and many surviving cells and to differentiate into various lineages, such as neurons and glial cells. Kurozumi and colleagues demon-were detected in the capsule. Rats receiving encapsulated VEGF-secreting cells displayed behavioral im-strated that mesenchymal stem cells (MSCs) from bone marrow, genetically engineered to secrete neurotrophic provement and highly preserved TH-positive fibers in the striatum and neurons in the substantia nigra pars factors, when transplanted into the striatum of middle cerebral artery occlusion (MCAO) stroke model of rats compacta. In addition, angiogenesis and glial proliferation were recognized around the capsule. The neuropro-led to the display of neurorescue effects (28) . The ability of MSCs to migrate over a wide area was of great ad-tection might be mediated by both indirect and direct mechanisms. VEGF may improve microcirculation by vantage to the dispersal of neurotrophic factors into the required region. A similar method using neural stem newly developed vessels or secrete trophic factors like GDNF by increased vessel permeability. In addition, cells was attempted in our laboratory by utilizing the PD model of rats, because immature stem cells can supply glial proliferation induced by VEGF may exert neuroprotection through the production and secretion of neurotrophic factor or growth factor as well as reinnervate with host tissues. In order to enhance the function GDNF or by the antioxidant effects of glial cells. Furthermore, the neuroprotective effects of VEGF might be of the growth factor resource, genetically engineered adult neural stem cells were transplanted into a PD rat closely linked to its ability to outcompete semaphorin3A (Sema3A), which is not only a well-known chemorepel-model. Adult neural stem cells were isolated from the subventricular zone (SVZ) where neural stem cells with lent factor for axonal growth, but also an apoptosis inducer, for access to the neuropilin (NP) receptor, thereby continuous neurogenesis resided. Neural stem cells were cultured using the neurosphere technique with epidermal blocking Sema3A-induced apoptosis (5, 55, 64) . Interestingly, Sema3A was connected to the toxicity of DA and growth factor for a few weeks, and then transfected using the fiber-mutant F/RGD adenovirus vector contain-6-OHDA for DA neurons (6,65). However, the role of Sema3A in PD remains unsolved, although the toxicity ing the GDNF gene (15, 61) . Following sufficient secretion of GDNF, they were transplanted into the rodent of high doses of Sema3A has been demonstrated in vitro (67) .
PD model. The genetically modified neural stem cells in this study had the same ability to differentiate into either After confirming the neuroprotective effects of VEGF, the therapeutic dose window was explored using differ-neurons or astrocytes. As a result, the transplanted rats showed behavioral improvement over time. Further-ent sizes of capsules with different amounts of VEGF secretion (69) . In the study, 100 ng/ml of VEGF in vitro more, the immunohistochemical investigation demonstrated many surviving transplanted cells and preserved and over 30 ng of VEGF from the large capsule led to deterioration of DA neuronal survival with exacerbated TH-positive fibers in the striatum and neurons in the greater impact than the establishment of deep brain stim-8. Bondanza, A.; Ciceri, F.; Bonini, C. Application of donor lymphocytes expressing a suicide gene for early GVL in-ulation. In addition, autologous cells can also be used duction and later control of GVH reactions after bonefor PD, although there is some concern about aged and 
